 Fellow Investor,
My father, Malcolm, taught me never to let a good opportunity go to waste.
So I'm taking this time to offer you the chance to join 12,420 other investors who subscribe to Forbes' flagship newsletter.
In 2000, we launched an unusual advisory for individual investors. Its mission: to find undervalued stocks that Wall Street overlooks. I'm talking about misunderstood, under covered, mispriced stocks that the "smart money" misses time and time again.
That advisory is Forbes Investor.
I'm here to tell you that 22 years later, Forbes Investor's gains well exceed our original goals.
Through my hand–picked editor Taesik Yoon's astute guidance, this renowned advisory has returned a massive 640%1 since inception compared to the 191% return from the S&P 500.
What’s more, much of this outperformance has been driven by the kind of small-cap value stocks that investors had largely ignored over the past several years in favor of the mega-cap growth stocks that powered much of the market’s strong returns over this period. Specifically, with the rich, inflated valuations of these mega-caps becoming too much for investors to stomach, this led to renewed interest in these attractively priced small-caps last year. This helped Forbes Investor soar 46.7% in 2021 and trounce the S&P 500, which was the best performing major market average with a gain of 26.9% over the same period.
More importantly, this preference for value has continued into 2022. As a result, the Forbes Investor is vastly outperforming ahead of the S&P 500 despite what has been a very tough year for the stock market thus far.2
But don't just take my word for it. Of the 34 stocks recommended since the start of 2021, 13—more than a third—have already been dropped with an average gain of over 21% on an average holding period of just 4-and-a-half-months. This includes recent winners such as Natus Medical (NTUS), American Vanguard (AVD), Natural Grocers (NGVC), Photronics (PLAB) and Edgewell Personal Care (EPC), which were only held for 4 months, 10 months, 6 months, 2 months and 2 months, respectively.
The result? A 46% surge in NTUS compared to 5% decline in the S&P 500 over the same span; a 28% gain in AVD versus just a 4% increase in the S&P 500; a 34% climb in NGVC, which is nearly ten times better than the less than 4% rise in the S&P 500; a 50% climb in PLAB that trounced the meager 4% increase in the S&P 5003; and a 32% jump in EPC that was more than fivefold better than the 6% gain in S&P 500.
If that's not impressive enough, take a look at some of the other fantastic profits booked over the past few years:
| Company | Return | S&P 500 | | Photronics (PLAB)4 | 29% | -8% | | The Hackett Group (HCKT) | 50% | 42% | | CRA International (CRAI) | 66% | 28% | | J2 Global (JCOM) | 36% | 17% | | Luxfer Holdings (LXFR) | 36% | 13% | | Veeco Instruments (VECO) | 30% | 2% | | Natural Grocers (NGVC) | 33% | 4% | | Tivity Health (TVTY) | 37% | -16% | | Sterling Construction (STRL) | 44% | 12% | | SP Plus (SP) | 20% | 6% | | Barrett Business Services (BBSI) | 33% | 3% | | Atkore International (ATKR) | 30% | 10% | | Berry Global (BERY) | 21% | 5% | | NeoPhotonics (NPTN) | 25% | 3% | | SpartanNash (SPTN) | 31% | 6% | | A10 Networks (ATEN) | 64% | 10% | But such undervalued market beating gems like these are becoming increasingly harder to find in a market dealing with so many major headwinds—including rising rates, ballooning inflation, raw material and labor shortages the likes of which we haven’t seen in years (and never at the same time), and of course, the unprovoked invasion of Ukraine by Russia. That makes active stock-selection strategies like ours—which are designed to identify the ones that have been unfairly beaten up under these challenging conditions and have the potential to handsomely reward their shareholders—even more important.
The good news is, with our current portfolio of recommendations selling at an average forward price-earnings (P/E) multiple of just 11.9 and at a steep discount to the S&P 500, which trades at a much higher 19.9 times its aggregate earnings estimate for 2022, it’s chock full of stocks with this potential5.
Joining today will get you immediate access to this portfolio and two new deeply-valued recommendations each month that have been carefully selected for their ability to outperform the broader market. Get access before these become the next winners to be featured on the list above.
I want to do everything in my power to help you put this exceptional advisory to work. That's why I'm sending this invitation and giving you a rare chance to try Forbes Investor at the lowest price ever.
Forbes Investor usually costs $197 a year, but until midnight tonight you can put Forbes Investor to work for you for just $49.
That's a massive 75% savings off the regular price. And it's less than the original Charter rate from 22 years ago.
So—don't delay this limited–time invitation expires at midnight tonight.
Please note, no exceptions or extensions will be granted. Once this offer is gone, it's gone for good. There's no better time to give yourself and your family a much–deserved financial boost. I hope you decide to take me up on this exclusive offer.
Sincerely,
Steve Forbes
Chairman and Editor–in–Chief
Forbes Media | 
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.